Lee Roy Morgan

1.2k total citations
57 papers, 829 citations indexed

About

Lee Roy Morgan is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lee Roy Morgan has authored 57 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lee Roy Morgan's work include Glioma Diagnosis and Treatment (5 papers), Cancer therapeutics and mechanisms (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Lee Roy Morgan is often cited by papers focused on Glioma Diagnosis and Treatment (5 papers), Cancer therapeutics and mechanisms (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Lee Roy Morgan collaborates with scholars based in United States, France and Russia. Lee Roy Morgan's co-authors include Branko S. Jursic, Blaise LeBlanc, Donna M. Neumann, David J. Adams, Edward T. Krementz, Wilfred L. Guerin, Mack R. Holdiness, Elmo J. Cerise, Dominic Fan and Lawrence J. Marnett and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Lee Roy Morgan

55 papers receiving 762 citations

Peers

Countries citing papers authored by Lee Roy Morgan

Since Specialization

Citations

This map shows the geographic impact of Lee Roy Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee Roy Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee Roy Morgan more than expected).

Fields of papers citing papers by Lee Roy Morgan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee Roy Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee Roy Morgan. The network helps show where Lee Roy Morgan may publish in the future.

Co-authorship network of co-authors of Lee Roy Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of Lee Roy Morgan. A scholar is included among the top collaborators of Lee Roy Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee Roy Morgan. Lee Roy Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment of recurrent metastatic uterine leiomyosarcoma of the spine: a multimodality approach using resection, radiosurgery, and chemotherapy 2015 ·Journal of Neurosurgery Spine ·Michael J. Strong, (unknown), (unknown), Roy S. Weiner, Lee Roy Morgan, (unknown)	10
2	Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development 2011 ·Current Medicinal Chemistry ·David J. Adams, Lee Roy Morgan	43
3	BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors 2010 ·Cancer Chemotherapy and Pharmacology ·David J. Adams, William R. Waud, Mansukh C. Wani, Govindarajan Manikumar, James L. Flowers, Timothy A. Driscoll, Lee Roy Morgan	5
4	Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents 2009 ·Cancer Chemotherapy and Pharmacology ·Lee Roy Morgan, Robert F. Struck, William R. Waud, Blaise LeBlanc, (unknown), Branko S. Jursic	14
5	Arylsulfatase B in colorectal cancer 2006 ·Cancer ·Lee Roy Morgan, (unknown), William Thomas, Edward T. Krementz, William R. Meeker	5
6	4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers 2005 ·Cancer Chemotherapy and Pharmacology ·(unknown), Patricia LoRusso, Leonard C. Thomas, (unknown), (unknown), (unknown), Karl Tornyos, Edward T. Krementz, Steven Parker, Lee Roy Morgan	5
7	Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide 2004 ·Cancer Chemotherapy and Pharmacology ·N. Germann, Saı̈k Urien, (unknown), Marion S. Ratterree, Robert F. Struck, William R. Waud, (unknown), Gérard Bastian, Branko S. Jursic, Lee Roy Morgan	11
8	Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of temozolomide against melanoma growing at the CNS site 2004 ·Cineca Institutional Research Information System (Tor Vergata University) ·Lucio Tentori, Carlo Leonetti, Marco Scarsella, (unknown), David C. Calvin, Lee Roy Morgan, Zhi Tang, Kinga Woźniak, (unknown), Randall Hoover, Rena G. Lapidus, Gabriella Zupi, (unknown), Grazia Graziani	1
9	Anticancer activity for 4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and Their abilities to interact with lymphoendothelial cell surface markers 2002 ·Bioorganic & Medicinal Chemistry Letters ·Lee Roy Morgan, Branko S. Jursic, (unknown), Donna M. Neumann, (unknown), Blaise LeBlanc	165
10	Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolite of penclomedine 2001 ·Cancer Chemotherapy and Pharmacology ·Robert F. Struck, (unknown), Henry S. Friedman, (unknown), Lee Roy Morgan, (unknown)	4
11	Anticancer Properties for 4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-Diaminophenothiazin-5-ium Double Salts 2001 ·Bioorganic & Medicinal Chemistry Letters ·Lee Roy Morgan, (unknown), Blaise LeBlanc, (unknown), Ying Yang, Branko S. Jursic, Richard B. Cole	7
12	High-performance liquid chromatographic determination of 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone in plasma 1995 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), S.Sankara Subramanian, Lee Roy Morgan	2
13	Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study 1995 ·Investigational New Drugs ·David J. Stewart, Lee Roy Morgan, Shailendra Verma, Jean A. Maroun, (unknown)	10
14	N-Alkylation of Aromatic and Heteroaromatic-2,4-dinitrophenylhydrazones with Potassium Fluoride on Alumina 1994 ·Synthetic Communications ·K. THANGARAJ, Lee Roy Morgan	9
15	Phytohemagglutinin (PHA) stimulated lymphocytes as systemic therapy for advanced renal cancer 1982 ·International Journal of Immunopharmacology ·Lee Roy Morgan, (unknown)	1
16	The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. 1981 ·PubMed ·(unknown), Lee Roy Morgan	11
17	Measurement of arylsulfatase A activity in urine. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), Lee Roy Morgan	13
18	Inhibition of DNA synthesis in harding-passey melanoma cells by prostaglandins A1 and A2: Comparison with chemotherapeutic agents 1979 ·Biochemical and Biophysical Research Communications ·Kenneth V. Honn, John R. Dunn, Lee Roy Morgan, Michael J. Bienkowski, Lawrence J. Marnett	46
19	Arylsulphatase and its relation to homovanillic acid in neuroblastomas 1972 ·Clinica Chimica Acta ·Lee Roy Morgan, Betty A. Maddux, (unknown), (unknown)	1
20	Acid-catalyzed Reactions between Carbonyl Compounds and Organic Azides. III. Aromatic Ketones¹ 1959 ·Journal of the American Chemical Society ·Joseph H. Boyer, Lee Roy Morgan	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact